Dr. Christina F. Lin, MD

Dr. Lin practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Lin's NPI, 1033745906, was assigned on March 22, 2020. Dr. Lin holds California license A182755.

Dr. Lin's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Lin's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Lin to 1 more hospital and 1 medical group, each named with a free account. Dr. Lin's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Lin is licensed in California.

CMS data shows 268 Medicare services from Dr. Lin across 4 procedure codes in 2024, for 75 Medicare patients. Medicare paid $26,479 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 75 Medicare patients who saw Dr. Lin in 2024. The largest group is 75 to 84, with 24 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 39% are also on Medicaid. Their average risk score is 3.26, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 58, with 60% women.

In 2024, Dr. Lin wrote 38 Medicare Part D claims for 14 patients. 89% of them were for generic drugs. CMS names the drug for 26 of them, across 2 drugs with 11 or more claims each, at $305 in total drug cost. In 2021, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Lin for performance year 2024, reported as part of a group. Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Dr. Lin, published from 2020 to 2024. 2024 was the busiest year, with 3. The most frequent topics are Stomach Neoplasms. Dr. Lin's most frequent co-authors are Vidhya Balasubramanian, MD, Nielsen Quimaira Fernandez-Becker, MD, PhD and Robert Jeffrey Huang, MD.

CMS Open Payments shows 1 general payment to Dr. Lin from 1 drug or device company in 2025. Food and beverage make up the largest share, 100% of the total. Galderma Laboratories, L.P. paid the most, $87.